Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tonapofylline, Adentri
BG9928 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | .03 mg/kg |
| 2 | EXPERIMENTAL | .15 mg/kg |
| 3 | EXPERIMENTAL | .3 mg/kg |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| tonapofylline | DRUG | IV |
| Placebo | DRUG | IV |
| BG9928 | DRUG | Oral 75 mg single dose |
Inclusion Criteria: * Previous diagnosis of heart failure. * Must have ADHF, requiring hospitalization, with clinical evidence for volume overload Exclusion Criteria: * History of an allergic reaction to any xanthine-containing substance. * History of seizure * History of stroke * Myocardial infa...
BG9928 is an investigational small molecule that Biogen Inc. studied in people with hepatic impairment, a condition in which liver function is reduced. It was evaluated in a Phase 1 trial to assess its behavior in subjects with impaired liver function compared with healthy volunteers.
BG9928 targets the A1 receptor, a receptor class molecular target. By acting at this receptor, the small molecule is designed to interact with adenosine A1 receptor signaling. This receptor activity is the basis for its investigation in hepatic impairment.
BG9928 is being developed by Biogen Inc., which trades on the Nasdaq under the ticker BIIB. Biogen sponsored the clinical program for the drug, including the Phase 1 study conducted in the United States.
BG9928 is in Phase 1 development. It is investigational and has not been approved by the FDA. The Phase 1 program consists of one completed trial, and no trials are currently active.
BG9928 was studied in one Phase 1 trial, NCT00858156, titled "BG9928 in Subjects With Hepatic Impairment." The trial enrolled 23 participants in the United States, included healthy volunteers, and is now completed.
The Phase 1 trial NCT00858156 was an uncontrolled study, meaning it did not use randomization or double blinding. It enrolled 23 participants aged 18 years and older of all sexes, included healthy volunteers, and was conducted in the United States.